<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364319">
  <stage>Registered</stage>
  <submitdate>29/05/2013</submitdate>
  <approvaldate>31/05/2013</approvaldate>
  <actrnumber>ACTRN12613000627752</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of the fixed combinations of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in sentinel sites of Melen (Estuary) and of Franceville (Haut Ogooue) in Gabon</studytitle>
    <scientifictitle>Efficacy and safety of the fixed combinations of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in sentinel sites of Melen (Estuary) and of Franceville (Haut Ogooue) in Gabon</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uncomplicated Plasmodium falciparum malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a surveillance study to monitor the efficacy and safety of the first-line (Arsucam) and second-line (Coartem) antimalarial treatments for uncomplicated falciparum malaria in children Gabon.  Eligible patients will be treated with either Arsucam or Coartem (adult tablet or pediatric dispersible tablet).  Both drugs will be tested in each of the two sentinel sites; allocation to treatment will be by randomization to avoid the risk of having insufficient patients in one of the two groups at the end of the study period.     Patients assigned to Arsucam will be treated with one of the three tablets strengths  formulation conatining 25 mg artesunate/67.5 mg  amodiaquine; 50 mg  artesunate/135 amodiaquine; 100 mg artesunate/270 mg amodiaquine.  Coartem  tablet containing 20 mg artemether and 120 mg lumefantrine will be used in children over 15 kg, and Coartem dispersible tablets containing 10 mg artemether and 60 mg lumefantrine will be used for children from 5 to 15 kg body weight. The tablets strength and number of tablets to be administered daily will be based on body weight according to standard of care.  Coartem daily dose will be administered twice a day and Coarsucam daily dose will be administered once a day.  Both treaments will be administered for three consecutive days by study staff.  Patients will be seen for clinical and parasitological evaluation, daily for the first 3 days, and then weekly until day 28 or at any time if symptoms re-occurred. </interventions>
    <comparator>None
</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients with adequate clinical and parasitological response adjusted by PCR (polymerase chain reaction)</outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nature and incidence of adverse events. Possible adverse events are those known to occur with antimalarials and include, headache, body ache nausea, vomiting, abdominal discomfort, liver enzyme elevation and dizziness. Clinical laboratory tests may be performed to confirm a diagnosis.</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Axillary temperature equal or greater than 37.5 degrees Celsius or history of fever in the past 24 hours.
Parasitemia, asexual forms between 2000 and 200 000 per microliter of blood.
Mono-infection with plasmodium falciparum confirmed by microscopy. 
Age between 12 months and 12 years.
Body weight greater than 5 kg.
Absence of clinical signs of severe malaria
Absence of known serious chronic disease.
Absence of severe malnutrition.
Capacity to swallow oral medication.
Capable and willing to follow protocol requirement including schedule of assessments
Consent from parent or guardian.
Assent from children aged 11 and 12 years.
  
</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Presence of general danger signs in children aged under 5 years, or signs of severe falciparum malaria according to WHO definition.
Mixed or mono-infection with another Plasmodium species detected by microscopy.
Presence of severe malnutrition (defined as a child whose growth standard is below minus 3z-score, has symmetrical oedema involving at least the feet, or has mid-upper arm circumference less than 110 mm.
Presence of febrile conditions due to diseases other than malaria (measles, acute lowest respiratory tract infection, severe dirrhoea with dehydration) or other known underlyning chronic diseases (cardiac, renal and hepatic diseases, HIV/AIDS).
Regular medication, which may interfere with animalarial pharmacokinetics;
History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatments
Likehood of pre-pubescence or pubescence in female.
Refusal to consent.
Not capable to comply with visit schedule.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>7/06/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/05/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>288</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Gabon</country>
      <state>Melen (Estuaire)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Gabon</country>
      <state>Franceville (Haut Ogooue)</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>PNLP Ministere de la Sante GABON</primarysponsorname>
    <primarysponsoraddress>c/o Dr Etienne  NZENGUE
B.P. 50 Libreville</primarysponsoraddress>
    <primarysponsorcountry>Gabon</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>PNLP Ministere de la Sante GABON
</fundingname>
      <fundingaddress>B.P. 50 Libreville</fundingaddress>
      <fundingcountry>Gabon</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Dr Thierry Fandeur
Centre International de Recherches Medicales de Franceville</othercollaboratorname>
      <othercollaboratoraddress>B.P. 769
Franceville</othercollaboratoraddress>
      <othercollaboratorcountry>Gabon</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Dr Marielle Bouyou-Akotet
Universite des Sciences de la Sante-GABON
Departement de Parasitologie et de Mycologie</othercollaboratorname>
      <othercollaboratoraddress>B.P. 4009
Libreville</othercollaboratoraddress>
      <othercollaboratorcountry>Gabon</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>An open-label study to monitor the efficacy and safety of the first and second line antimalarials, artesuante-amodiaquine (Arsucam) and artemether-lumefantrine (Coartem)  for the treatment of uncomplicated falciparum malaria in children in Melen (Estuaire) and in Franceville (Haut-Ogooue) in Gabon. The primary outcome is the proportion of patients with adequate clinical and parasitological response PCR-adjusted at day 28. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Research Committee, World Health Organisation</ethicname>
      <ethicaddress>20 Ave Appia
1211 Gneva 27</ethicaddress>
      <ethicapprovaldate>21/05/2013</ethicapprovaldate>
      <hrec>RPC 567</hrec>
      <ethicsubmitdate>18/03/2013</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Thierry Fandeur</name>
      <address>Centre International de Recherches Medicales de Franceville
B.P. 769
Franceville</address>
      <phone>+241 07 61 57 70</phone>
      <fax />
      <email>thierryfandeur@yahoo.fr</email>
      <country>Gabon</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Etienne NZENGUE</name>
      <address>PNLP Ministere de la Sante GABON
B.P. 50 Libreville</address>
      <phone>+241 77 56 43</phone>
      <fax />
      <email>nzenguetienne@yahoo.fr</email>
      <country>Gabon</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Thierry Fandeur</name>
      <address>Centre International de Recherches Medicales de Franceville
B.P. 769
Franceville</address>
      <phone>+241 07 61 57 70</phone>
      <fax />
      <email>thierryfandeur@yahoo.fr</email>
      <country>Gabon</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Psacal Ringwald</name>
      <address>World Health Organisation
20 Ave Appia
1211 Geneva 27</address>
      <phone>+41 22 791 3469</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>